| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
Laboratory of Molecular Immunology, Center for Neurologic Diseases, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA 02115; and
Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02115
Rapamycin is a fungal macrolide that inhibits the proliferation of T cells. Studies in both animals and humans have found that rapamycin significantly reduces graft rejection. However, though CD8+ T cells are involved in graft infiltration and rejection, little is known regarding the effects of rapamycin on CD8+ human T cell responses. In this study, we examined the mechanism of rapamycin-induced inhibition of Ag-driven activation of CD8+ T cells. Surprisingly, a heterogeneous proliferative response in the presence of rapamycin was observed among different Ag-specific CD8+ T cell clones; this was also observed in CD8+ peripheral blood T cells activated with TCR cross-linking ex vivo. Inhibition of T cell proliferation by rapamycin was controlled by both the strength of signal delivered through the Ag receptor as well as the specific costimulatory signals received by the T cell. Rapamycin-resistant proliferation occurred despite inhibition of p70s6 kinase activity. Moreover, rapamycin-resistant proliferation of the CD8+ T cell clones was blocked by anti-IL-2 Abs, suggesting that while some of the parallel pathways triggered by IL-2R signaling are sensitive to the effects of rapamycin, others account for the Ag-driven rapamycin resistance. These data provide a new framework for examining the specific mechanism of action of rapamycin in human disease.
This article has been cited by other articles:
|
|
 |
|
  R. Zeiser, D. B. Leveson-Gower, E. A. Zambricki, N. Kambham, A. Beilhack, J. Loh, J.-Z. Hou, and R. S. Negrin Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells Blood, January 1, 2008; 111(1): 453 - 462. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Cutler, S. Li, V. T. Ho, J. Koreth, E. Alyea, R. J. Soiffer, and J. H. Antin Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation Blood, April 1, 2007; 109(7): 3108 - 3114. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. R. Lock, S. H. Sacks, and M. G. Robson Rapamycin at subimmunosuppressive levels inhibits mesangial cell proliferation and extracellular matrix production Am J Physiol Renal Physiol, January 1, 2007; 292(1): F76 - F81. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Colombetti, V. Basso, D. L. Mueller, and A. Mondino Prolonged TCR/CD28 Engagement Drives IL-2-Independent T Cell Clonal Expansion through Signaling Mediated by the Mammalian Target of Rapamycin. J. Immunol., March 1, 2006; 176(5): 2730 - 2738. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Fox, P. S. Hammerman, and C. B. Thompson The Pim kinases control rapamycin-resistant T cell survival and activation J. Exp. Med., January 18, 2005; 201(2): 259 - 266. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Slavik, D.-G. Lim, S. J. Burakoff, and D. A. Hafler Rapamycin-resistant Proliferation of CD8+ T Cells Correlates with p27kip1 Down-regulation and bcl-xL Induction, and Is Prevented by an Inhibitor of Phosphoinositide 3-Kinase Activity J. Biol. Chem., January 9, 2004; 279(2): 910 - 919. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Colombetti, F. Benigni, V. Basso, and A. Mondino Clonal Anergy Is Maintained Independently of T Cell Proliferation J. Immunol., December 1, 2002; 169(11): 6178 - 6186. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Boylan, P. Anand, and P. A. Gruppuso Ribosomal Protein S6 Phosphorylation and Function during Late Gestation Liver Development in the Rat J. Biol. Chem., November 21, 2001; 276(48): 44457 - 44463. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
